Skip to main content
Top
Published in: Critical Care 1/2004

01-02-2004 | Poster presentation

Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study

Authors: C Garratt, M Packer, W Colucci, L Fisher, B Massie, J Teerlink, J Young

Published in: Critical Care | Special Issue 1/2004

Login to get access

Excerpt

Traditionally, intravenous (IV) drugs in decompensated heart failure (HF) have been evaluated based on their hemodynamic effects. Thus, no endpoint to measure symptomatic improvement in decompensated HF has yet been validated. To do so, we adapted the clinical composite (which has been validated in trials of chronic HF) to the evaluation of IV levosimendan in a pilot trial of acute decompensated HF (REVIVE-1). …
Metadata
Title
Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study
Authors
C Garratt
M Packer
W Colucci
L Fisher
B Massie
J Teerlink
J Young
Publication date
01-02-2004
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2004
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc2556

Other articles of this Special Issue 1/2004

Critical Care 1/2004 Go to the issue